- Through proprietary laboratory technology and AI, Omniscope is building the world’s largest Immune Databank
- This transaction proves Buenavista’s continued commitment to leverage its expertise in Artificial Intelligence, Deep Tech and Healthcare
Madrid, February 25th, 2025.
Buenavista Equity Partners, a private equity group specialising in the lower/mid-market segment in Spain, announced today its strategic investment in Omniscope, a fast-growing technology company at the crossroads of biotechnology and data science decoding the immune system. Co-founded by Vijay Vaswani, Holger Heyn and Lynnette Ang, Omniscope has quickly established itself as a leader in empowering key decision makers in the medical sector with cutting-edge data insights through its innovative platform.
Omniscope leverages proprietary technology to build the world’s largest immune databank, generating high-resolution immune insights to inform therapy and develop diagnostics through a convergence of deep immune profiling and advanced Artificial Intelligence. Omniscope’s technology speeds up medical research and shortens the timeline from research to real-world human impact, having the potential to save millions of lives. In doing so, Omniscope represents a new standard in immune health and driving breakthroughs in personalized medicine.
The investment, carried out through the Buenavista Ventures fund, is set to accelerate Omniscope’s growth, supporting its mission to simplify complex data for organizations of all sizes. Omniscope’s platform is already transforming how industries—from healthcare to retail—leverage data to drive decisions and create value.
“We are thrilled to partner with Omniscope and its visionary co-founders, Vijay, Holger and Lynnette, whose leadership and technical expertise have been instrumental in building a truly groundbreaking solution,” said Joaquim Hierro, Managing Director at Buenavista Ventures. “Their commitment to innovation and their deep understanding of the market make them an ideal partner for our portfolio.
“We are excited to welcome Buenavista Equity Partners as a strategic investor,” said Vijay Vaswani, Co-founder and CEO of Omniscope. “Their support will enable us to expand our capabilities, reach more customers globally, and continue pushing the boundaries of immune data intelligence.”
With €150 million under management in 2023, the funds in the Buenavista Ventures area focus their investment on startups and entrepreneurs fostering technological and digital innovation. This investment marks Buenavista Equity Partners’ continued commitment to leverage its expertise in Artificial Intelligence, Deep Tech and Healthcare, supporting innovative companies that redefine industries and deliver long-term value.
